Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?

Diabetes Research and Clinical Practice

Volumn 90, Issue 2, 2010, Pages

  Chen, Ching Chu ^a,b   Chiang, An Na ^b   Hsieh, Min Huang ^c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II receptor blocker; DM

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA GALACTOSIDASE; CYTOMEGALOVIRUS VECTOR; DEOXYGLUCOSE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; IRBESARTAN; LOSARTAN; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAMIPRIL; ROSIGLITAZONE; UNCLASSIFIED DRUG; VIRUS VECTOR;

CELL LINE; CELL STRAIN 3T3; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE CONSTRUCT; GLUCOSE TRANSPORT; HUH 7 CELL; HUMAN; HUMAN CELL; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONVIRAL GENE DELIVERY SYSTEM; REPORTER GENE;

3T3-L1 CELLS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; MICE; RAMIPRIL; TREATMENT FAILURE;

EID: 77957754014     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.05.028     Document Type: Letter

References (4)

1. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the rennin-angiotensin system. Drugs 2004, 64:2537-2565.
2. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562. The DREAM Trial Investigators.
3. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, The NAVIGATOR Study Group. 10.1056/NEJMoa1001121.
4. Chen C.C., Hsiang C.Y., Chiang A.N., Lo H.Y., Li C.I. Peroxisome proliferator-activated receptor gamma transactivation-mediated potentiation of glucose uptake by Bai-Hu-Tang. J Ethnopharmacol 2008, 118:46-50.